Pfizer eyes big drop in Covid-related revenues in 2023 / Photo: © AFP/File
-
Indonesia battles Mount Bromo wildfire as El Nino takes root
-
PU Prime Expands Gold Trading with the Launch of XAUUSD247
-
STARCARES Revamps Basketball Court at the University of Lagos for Future Healthcare Professionals
-
Oil extends gains and stocks mostly down on fresh Hormuz worries
-
Eight dead, including teen suspect's grandparents, in Thailand shooting
-
Four dead, 15 injured in Thailand school shooting: deputy minister
-
Indonesia traps monkey to end rampage that wounded 18 people
-
Military shake-up poses little threat to Ukraine's drone revolution
-
Food security fears mount as UK farmers battle drought
-
Camels find unlikely home in outback Australia
-
Houthi missile attacks kill 58 Saudi-backed Yemeni govt forces
-
Pacific nations fail to agree on statement condemning China missile test
-
Chinese activist held in Bangkok finds Canada refuge
-
Anguish and hope: why a Tibetan set himself on fire in New York
-
Kiss takes reins as Wallabies face Japan
-
Oil extends gains and stocks fall on fresh Hormuz worries
-
North Korea touts dog soup and other home-cooked recipes to beat the heat
-
Venezuela's political transition talks wrap first day in Caracas
-
UK observatory nervously watches growing space junk threat
-
South Africa coach Erasmus wary of struggling Argentina
-
Meta ordered to pay US state $567 mn to abate 'public nuisance' and child harm
-
Actress, engineer, jihadist's widow among Syria's new women MPs
-
Houthi missile attacks kill 58 Saudi-backed Yemeni govt forces: source
-
Battling Norrie survives match point to oust de Minaur
-
No.1 Sabalenka and Pegula advance at Toronto
-
US firm takes on backyard mosquitoes -- with 600,000 mosquitoes
-
China missile test top of agenda as Pacific diplomats meet in Fiji
-
Thousands protest private property legislation in Argentina
-
Most UK teens to opt out of planned social media curfew: poll
-
Battling Norrie survives match point to oust de Minaur at Montreal
-
Venezuela's political transition talks launch in Caracas
-
Venezuela's political transition talks start: AFP
-
2 killed, 13 wounded in bus blast near Syrian capital: state media
-
Real Madrid extend Vinicius deal, sign Diomande in title bid boost
-
All Blacks skipper Taylor cautiously recovering from calf strain
-
PSG sign France midfielder Akliouche from Monaco
-
UN chief denounces Russia, Ukraine for civilian deaths
-
CONMEBOL 'expresses concern regarding repeated unilateral actions' by FIFA
-
UEFA turn up the pressure on Infantino and repeat boycott threat
-
Warren coy over whether Fury-Joshua will be in UK or US
-
Rodri approves Barcelona transfer talks with Man City: Barca source to AFP
-
Taiwan blocks key bridge in drill for potential Chinese invasion
-
Venezuela unable to tally missing from cataclysmic quakes
-
Migrant children risk abuse on streets of Ceuta, aid groups warn
-
Le Court sprints to stage six Tour de France Femmes win
-
Oil price shoots up as stocks tread water
-
Doping body says Parker's positive cocaine test caused by nutritionist
-
British Grand Prix stays on MotoGP calendar until 2028
-
UEFA says boycott of World Cups stands despite FIFA backdown on private investment
-
Britain's EasyJet flies into US hands as takeover confirmed
Pfizer eyes big drop in Covid-related revenues in 2023
After two straight years of surging sales due to Covid-19 products, Pfizer projected a steep decline in 2023 revenues as demand for vaccines and therapeutics ebbs.
The pharma giant expects about a 30 percent drop in company revenues this year as governments work off excess inventories of Pfizer's coronavirus-related products and consumer demand wanes in some markets.
Sales for the vaccine Comirnaty and the Covid-9 therapeutic Paxlovid will reach a "low point" this year before rebounding somewhat in 2024, the company said.
The hit means Pfizer expects 2023 revenues of between $67-71 billion, down about 30 percent from the 2022 level.
Pfizer's revenues rose by nearly a quarter between 2021 and 2022 after almost doubling in the prior stretch.
Pfizer expects 2024 sales of Covid products to stabilize, said Chief Executive Albert Bourla.
"Then starting in 2025 and continuing in 2026 and beyond, we expect to see an increase in Covid-19 vaccination rates, assuming the successful development and approval of a Covid-flu combination product," Bourla said in prepared remarks.
Pfizer projected that 24 percent of the US population would receive a Covid-19 vaccine in 2023, down from the 31 percent level in 2022.
But Bourla said the combined Covid/flu vaccine could bring the level in line with the current flu shot benchmark of about 50 percent of all Americans.
Pfizer expects increased uptick for its Covid therapeutic in China. The company has agreements in China with one company to import and distribute Paxlovid and with another Chinese enterprise to manufacture the drug locally.
"Pfizer shipped only tens of thousands of courses to China in fiscal 2022," Bourla said. "From December through March we expect to ship millions of courses to meet local demand."
In terms of overall fourth-quarter earnings, Pfizer reported profits of $5.0 billion, up 47 percent from the year-ago period.
Revenues rose two percent to $24.3 billion.
Pfizer said it is also hard at work on non-Covid output, planning 19 new products over an 18-month period.
Shares of Pfizer declined 0.3 percent to $43.44 in early Tuesday trade.
C.Meier--BTB
